# JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

> **NCT07115706** · — · NOT_YET_RECRUITING · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 7150 (estimated)

## Conditions studied

- Erosive Gastroesophageal Reflux Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07115706
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 7150 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115706, "JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07115706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*